SG11201807523PA - Ilt7 binding molecules and methods of using the same - Google Patents

Ilt7 binding molecules and methods of using the same

Info

Publication number
SG11201807523PA
SG11201807523PA SG11201807523PA SG11201807523PA SG11201807523PA SG 11201807523P A SG11201807523P A SG 11201807523PA SG 11201807523P A SG11201807523P A SG 11201807523PA SG 11201807523P A SG11201807523P A SG 11201807523PA SG 11201807523P A SG11201807523P A SG 11201807523PA
Authority
SG
Singapore
Prior art keywords
medimmune
international
gaithersburg
llc
rule
Prior art date
Application number
SG11201807523PA
Inventor
Katherine Vousden
Julie Douthwaite
Melissa Damschroder
Miguel Sanjuan
Original Assignee
Viela Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Viela Bio Inc filed Critical Viela Bio Inc
Publication of SG11201807523PA publication Critical patent/SG11201807523PA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39566—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against immunoglobulins, e.g. anti-idiotypic antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2017/156298 Al 14 September 2017 (14.09.2017) WIPO I PCT (51) International Patent Classification: A61K 39/395 (2006.01) C12N 15/13 (2006.01) C07K 16/28 (2006.01) C12P 21/08 (2006.01) C07K 16/46 (2006.01) (21) International Application Number: PCT/US2017/021616 (22) International Filing Date: 9 March 2017 (09.03.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/306,125 10 March 2016 (10.03.2016) US (71) Applicant: MEDIMMUNE, LLC [US/US]; One MedIm- mune Way, Gaithersburg, MD 20878 (US). (72) Inventors: VOUSDEN, Katherine, Ann; c/o MedImmune Limited, Milstein Building, Granta Park, Cambridge CB21 6GH (GB). DOUTHWAITE, Julie, Ann; c/o MedImmune Limited, Milstein Building, Granta Park, Cambridge CB21 6GH (GB). DAMSCHRODER, Melissa, Marie; c/o MedImmune LLC, One MedImmune Way, Gaithersburg, MD 20878 (US). SANJUAN, Miguel, Angel; c/o MedIm- mune LLC, One MedImmune Way, Gaithersburg, MD 20878 (US). (74) Agents: OYLOE, Jacob et al.; c/o MedImmune, LLC, One MedImmune Way, Gaithersburg, MD 20878 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: as to applicant's entitlement to apply for and be granted a patent (Rule 4.1700) as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) Published: with international search report (Art. 21(3)) with sequence listing part of description (Rule 5.2(a)) = (54) Title: ILT7 BINDING MOLECULES AND METHODS OF USING THE SAME Alignment VH : #2 -VH QVQLQQSGAELVKPGASVEMSCKAFGYTFO WME(QNHGKSLEWItarH 60 10D10 - via EVQLVESGGGVVQPGRELRLSCAASGFTFS . ri - F , IEWVRQAPGQGLEWIi ' , F - HIZYNDLITY 60 7C 7 -VH EVQLVESGGGVVQPGRSLRLSCAASGET QAPGQGLEW 60 #28 -VH NEKFKGKAKLTVEKSSSTVYLELSRLTSDDSAVYYCARGOOGU=MIGQGTSVTVSS 117 10D10 -VH NEKFKGRVIIITTDTSTSTVYMELSSLRSEDTAVYYCTRGE WGQGTLVTVSS 117 7C7-VH NEKFKGRVTMTTDTSTSTVYMELSSLRSEDTAVYYCTR GQGTLVTVSS 117 Figure lA (57) : The present invention is directed to ILT7 binding molecules, e.g., anti-ILT7 antibodies, and methods for treating or preventing conditions and diseases associated with ILT7-expressing cells such as autoimmune diseases. 111111111111110111011111111111010111110111011111111111110111111110111111111110111111 W O 20 17 / 15 6 298 Al
SG11201807523PA 2016-03-10 2017-03-09 Ilt7 binding molecules and methods of using the same SG11201807523PA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662306125P 2016-03-10 2016-03-10
PCT/US2017/021616 WO2017156298A1 (en) 2016-03-10 2017-03-09 Ilt7 binding molecules and methods of using the same

Publications (1)

Publication Number Publication Date
SG11201807523PA true SG11201807523PA (en) 2018-09-27

Family

ID=59790876

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201807523PA SG11201807523PA (en) 2016-03-10 2017-03-09 Ilt7 binding molecules and methods of using the same
SG10202008769SA SG10202008769SA (en) 2016-03-10 2017-03-09 Ilt7 binding molecules and methods of using the same

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10202008769SA SG10202008769SA (en) 2016-03-10 2017-03-09 Ilt7 binding molecules and methods of using the same

Country Status (17)

Country Link
US (3) US11072652B2 (en)
EP (1) EP3426298A4 (en)
JP (3) JP6979976B2 (en)
KR (4) KR102632796B1 (en)
CN (2) CN109414499B (en)
AR (2) AR109450A1 (en)
AU (1) AU2017231833B2 (en)
BR (1) BR112018067951A2 (en)
CA (1) CA3017197A1 (en)
IL (1) IL261653A (en)
MX (1) MX2018010771A (en)
RU (1) RU2756109C2 (en)
SG (2) SG11201807523PA (en)
TW (1) TWI755380B (en)
UA (1) UA127731C2 (en)
WO (1) WO2017156298A1 (en)
ZA (1) ZA201806597B (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017231833B2 (en) 2016-03-10 2024-03-14 Viela Bio, Inc. ILT7 binding molecules and methods of using the same
WO2018119425A2 (en) * 2016-12-22 2018-06-28 Icahn School Of Medicine At Mount Sinai Anti-lilrb3 antibodies and methods of use thereof
CN114008076A (en) * 2019-04-19 2022-02-01 艾洛基治疗公司 Antibodies to 4G 7-derived chimeric antigen receptor
CA3159511A1 (en) * 2019-12-06 2021-06-10 William Rees Methods of treatment using ilt7 binding proteins
CA3164042A1 (en) * 2019-12-20 2021-06-24 Medimmune, Llc Compositions and methods of treating cancer with chimeric antigen receptors targeting glypican 3
WO2021203013A2 (en) * 2020-04-03 2021-10-07 Viela Bio, Inc. Methods of treating immune mediated pulmonary injury
JP2024516698A (en) 2021-05-04 2024-04-16 ビエラ バイオ インコーポレイテッド Methods for treating autoimmune diseases using ILT7 binding proteins
WO2024026388A1 (en) 2022-07-27 2024-02-01 Viela Bio, Inc. Formulations comprising an immunoglobulin-like transcript 7 (ilt7)-binding protein

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2096948A (en) 1935-12-20 1937-10-26 Anchor Steel & Conveyor Co Conveyer system
US4741900A (en) 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4873192A (en) 1987-02-17 1989-10-10 The United States Of America As Represented By The Department Of Health And Human Services Process for site specific mutagenesis without phenotypic selection
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
AU4308689A (en) 1988-09-02 1990-04-02 Protein Engineering Corporation Generation and selection of recombinant varied binding proteins
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
ZA902949B (en) 1989-05-05 1992-02-26 Res Dev Foundation A novel antibody delivery system for biological response modifiers
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
AU7247191A (en) 1990-01-11 1991-08-05 Molecular Affinities Corporation Production of antibodies using gene libraries
US5780225A (en) 1990-01-12 1998-07-14 Stratagene Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules
ATE139258T1 (en) 1990-01-12 1996-06-15 Cell Genesys Inc GENERATION OF XENOGENE ANTIBODIES
US5314995A (en) 1990-01-22 1994-05-24 Oncogen Therapeutic interleukin-2-antibody based fusion proteins
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
US5698426A (en) 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
DK0564531T3 (en) 1990-12-03 1998-09-28 Genentech Inc Enrichment procedure for variant proteins with altered binding properties
IE921169A1 (en) 1991-04-10 1992-10-21 Scripps Research Inst Heterodimeric receptor libraries using phagemids
PT1024191E (en) 1991-12-02 2008-12-22 Medical Res Council Production of anti-self antibodies from antibody segment repertoires and displayed on phage
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
EP0733070A1 (en) 1993-12-08 1996-09-25 Genzyme Corporation Process for generating specific antibodies
ES2247204T3 (en) 1994-01-31 2006-03-01 Trustees Of Boston University BANKS OF POLYCLONAL ANTIBODIES.
US5516637A (en) 1994-06-10 1996-05-14 Dade International Inc. Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
DE4440354A1 (en) 1994-11-11 1996-05-15 Hoechst Schering Agrevo Gmbh Combinations of phenylsulfonylurea herbicides and safeners
ES2176484T3 (en) 1995-08-18 2002-12-01 Morphosys Ag PROTEIN BANKS / (POLI) PEPTIDES.
US6706484B1 (en) 1995-08-18 2004-03-16 Morphosys Ag Protein/(poly)peptide libraries
JP2978435B2 (en) 1996-01-24 1999-11-15 チッソ株式会社 Method for producing acryloxypropyl silane
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
CA2339889C (en) 1999-07-02 2012-01-31 Morphosys Ag Identification of specific binding partners binding to (poly)peptides encoded by genomic dna fragments or ests
US6849425B1 (en) 1999-10-14 2005-02-01 Ixsys, Inc. Methods of optimizing antibody variable region binding affinity
CN1461310B (en) 2000-02-10 2013-06-12 雅培制药有限公司 ANtibodies that bind human interleukin-18 and methods of making and using
US6897067B2 (en) 2000-11-03 2005-05-24 Regents Of The University Of Michigan Surface transfection and expression procedure
CA2429544C (en) 2000-11-17 2010-10-19 University Of Rochester In vitro methods of producing and identifying immunoglobulin molecules in eukaryotic cells
US20030148316A1 (en) 2001-08-01 2003-08-07 Lipford Grayson B. Methods and compositions relating to plasmacytoid dendritic cells
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
CA3077873A1 (en) 2002-03-20 2003-10-02 Catalina Marketing Corporation Targeted incentives based upon predicted behavior
EP2316922B1 (en) 2002-05-24 2013-05-22 Merck Sharp & Dohme Corp. Neutralizing human anti-IGFR antibody
WO2004023973A2 (en) 2002-09-12 2004-03-25 Incyte Corporation Molecules for diagnostics and therapeutics
JPWO2005007800A1 (en) * 2003-07-18 2007-04-12 持田製薬株式会社 Anti-platelet membrane glycoprotein VI monoclonal antibody
US9208495B2 (en) 2003-10-06 2015-12-08 Yellowpages.Com Llc Methods and apparatuses for advertisement presentation
GB0417487D0 (en) 2004-08-05 2004-09-08 Novartis Ag Organic compound
MX2007009466A (en) * 2005-02-10 2007-12-07 Baylor Res Inst Anti-interferon alpha monoclonal antibodies and methods for use.
WO2006124269A2 (en) * 2005-05-16 2006-11-23 Amgen Fremont Inc. Human monoclonal antibodies that bind to very late antigen-1 for the treatment of inflammation and other disorders
AU2012244391B2 (en) 2005-12-20 2014-09-11 Sbi Biotech Co., Ltd. Anti-ILT7 antibody
RU2456298C2 (en) 2005-12-20 2012-07-20 ЭсБиАй БАЙОТЕК КО., ЛТД. Ilt17 antibody
WO2007118214A2 (en) * 2006-04-07 2007-10-18 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Antibody compositions and methods for treatment of neoplastic disease
US7993648B2 (en) 2006-05-03 2011-08-09 The Regents of the Universitry of Colorado Immunostimulatory regimen comprising administering type 1 interferon and agonistic anti-CD40 antibody
US7781306B2 (en) 2007-06-20 2010-08-24 Semiconductor Energy Laboratory Co., Ltd. Semiconductor substrate and method for manufacturing the same
US20110311558A1 (en) 2008-12-01 2011-12-22 The Board Of Regents Of The University Of Texas System Recombinant Bone Marrow Stromal Antigen-2 in the Treatment of Autoimmune Diseases
CN102753704A (en) 2009-09-03 2012-10-24 米迪缪尼有限公司 Type 1 interferon diagnostic
EP2496600A1 (en) * 2009-11-04 2012-09-12 Fabrus LLC Methods for affinity maturation-based antibody optimization
US20140056889A1 (en) 2011-04-26 2014-02-27 Genentech, Inc. Compositions and method for treating autoimmune diseases
CN103732738A (en) 2011-04-28 2014-04-16 小利兰斯坦福大学托管委员会 Identification of polynucleotides associated with a sample
US9427464B2 (en) 2011-11-22 2016-08-30 Chiome Bioscience Inc. Anti-human TROP-2 antibody having an antitumor activity in vivo
PL2809683T3 (en) * 2012-01-31 2019-03-29 Sbi Biotech Co., Ltd. Anti-phospholipase d4 antibody
US8605807B1 (en) 2012-05-22 2013-12-10 Nigel Iain Stuart Macrae Communicating distinct data over a single frequency using multiple linear polarized signals
EA034963B1 (en) * 2012-11-08 2020-04-13 Клиасайд Байомедикал, Инк. Method of treating a posterior segment of the eye disorder
US9114438B2 (en) 2013-05-21 2015-08-25 Applied Materials, Inc. Copper residue chamber clean
MA40528A (en) * 2014-08-29 2017-07-05 Sorrento Therapeutics Inc Antibody therapeutics that bind oprf and opri
AU2017231833B2 (en) 2016-03-10 2024-03-14 Viela Bio, Inc. ILT7 binding molecules and methods of using the same
CA3159511A1 (en) 2019-12-06 2021-06-10 William Rees Methods of treatment using ilt7 binding proteins
JP2024516698A (en) 2021-05-04 2024-04-16 ビエラ バイオ インコーポレイテッド Methods for treating autoimmune diseases using ILT7 binding proteins

Also Published As

Publication number Publication date
IL261653A (en) 2018-10-31
CN109414499B (en) 2022-05-17
US20220144940A1 (en) 2022-05-12
KR20240017421A (en) 2024-02-07
JP2022043038A (en) 2022-03-15
KR102632796B1 (en) 2024-02-02
WO2017156298A1 (en) 2017-09-14
AU2017231833A1 (en) 2018-10-11
ZA201806597B (en) 2023-04-26
CN114874322A (en) 2022-08-09
MX2018010771A (en) 2019-05-15
RU2756109C2 (en) 2021-09-28
CN109414499A (en) 2019-03-01
KR102603010B1 (en) 2023-11-16
US11673950B2 (en) 2023-06-13
US11072652B2 (en) 2021-07-27
SG10202008769SA (en) 2020-10-29
AR122196A2 (en) 2022-08-24
KR102439395B1 (en) 2022-09-05
BR112018067951A2 (en) 2019-02-05
RU2018135550A3 (en) 2020-07-23
EP3426298A1 (en) 2019-01-16
US20230250167A1 (en) 2023-08-10
US20200339673A1 (en) 2020-10-29
KR20230148266A (en) 2023-10-24
JP6979976B2 (en) 2021-12-15
EP3426298A4 (en) 2019-11-27
AU2017231833B2 (en) 2024-03-14
KR20220123344A (en) 2022-09-06
UA127731C2 (en) 2023-12-20
TWI755380B (en) 2022-02-21
RU2018135550A (en) 2020-04-10
CA3017197A1 (en) 2017-09-14
JP2019516392A (en) 2019-06-20
JP7354212B2 (en) 2023-10-02
AR109450A1 (en) 2018-12-12
KR20180138201A (en) 2018-12-28
JP2024009808A (en) 2024-01-23
TW201742874A (en) 2017-12-16

Similar Documents

Publication Publication Date Title
SG11201807523PA (en) Ilt7 binding molecules and methods of using the same
SG11201808622SA (en) Chimeric receptors to flt3 and methods of use thereof
SG11201804373VA (en) Compositions and methods for immunooncology
SG11201809912UA (en) Hybrid carriers for nucleic acid cargo
SG11201806624XA (en) Deposition of molybdenum thin films using a molybdenum carbonyl precursor
SG11201804787UA (en) Human immunodeficiency virus neutralizing antibodies
SG11201900480YA (en) Anti-tim-3 antibodies
SG11201811431VA (en) Multispecific antibodies against cd40 and cd137
SG11201907561PA (en) Anti-lag-3 antibodies and uses thereof
SG11201804510PA (en) Biparatopic polypeptides antagonizing wnt signaling in tumor cells
SG11201407580YA (en) Composition comprising two antibodies engineered to have reduced and increased effector function
SG11201805001UA (en) Method of treating influenza a
SG11201810927QA (en) Pd-l1-specific antibodies and methods of using the same
SG11201806342SA (en) Glucagon and glp-1 co-agonists for the treatment of obesity
SG11201809374VA (en) Cd40l-fc fusion polypeptides and methods of use thereof
SG11201807827VA (en) Process for the preparation of pegylated drug-linkers and intermediates thereof
SG11201807041PA (en) Improved preparations of adult liver progenitor cells
SG11201909680UA (en) Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds
SG11201907434RA (en) Compositions and methods for immunooncology
SG11201907927SA (en) Binding molecules that specifically bind to tau
SG11201900845YA (en) Uses of il-13 antagonists for treating atopic dermatitis
SG11201809531SA (en) BINDING MOLECULES SPECIFIC FOR FCγGAMMA RIIA AND USES THEREOF
SG11201805311XA (en) Method of treating a mammal, including human, against cancer using methionine and asparagine depletion
SG11201804704PA (en) Compositions and methods for decreasing tau expression
SG11201909807TA (en) Methods of manufacturing of niraparib